260. シトステロール血症 Sitosterolemia Clinical trials / Disease details
臨床試験数 : 13 / 薬物数 : 13 - (DrugBank : 4) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 1
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00092898 (ClinicalTrials.gov) | October 2004 | 23/9/2004 | An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to An Ongoing Regimen of Ezetimibe 10 mg in Patients Homozygous Sitosterolemia | Lipid Metabolism, Inborn Errors;Heart Disease | Drug: MK0653, ezetimibe;Drug: Comparator: placebo | Organon and Co | NULL | Completed | 18 Years | 85 Years | All | 30 | Phase 3 | United States |
2 | NCT00092807 (ClinicalTrials.gov) | February 12, 2001 | 23/9/2004 | Sitosterolemia Extension Study (0653-003)(COMPLETED) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia - 1 Year Open-Label Extension | Lipid Metabolism, Inborn Errors;Heart Disease | Drug: MK0653, ezetimibe;Drug: Comparator: placebo | Organon and Co | NULL | Completed | 10 Years | N/A | All | 37 | Phase 3 | United States |
3 | NCT00092820 (ClinicalTrials.gov) | February 12, 2001 | 23/9/2004 | Sitosterolemia Extension Study (0653-004)(COMPLETED) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia | Lipid Metabolism, Inborn Errors;Heart Disease | Drug: MK0653, ezetimibe;Drug: Comparator: placebo | Organon and Co | NULL | Completed | 10 Years | N/A | All | 58 | Phase 3 | NULL |